NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID Switzerland/Stans

NLS Pharmaceutics Announces Preclinical Data Demonstrating

the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID

Switzerland/Stans, October 14, 2021 - NLS

Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company

focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders,

announces preclinical data for NLS-4 (Lauflumide), the Company's next-generation wake-promoting

drug candidate, which has shown promise for the treatment of chronic fatigue associated with Long-COVID (also known as "chronic

the preclinical study in which rats that had undergone a procedure to induce chronic fatigue recovered following treatment with NLS-4

and were able to exhibit typical nighttime activity when rats are normally active. Moreover, the NLS-4 treated rats had greater

motor-stimulating behavior compared to rats treated with modafinil, a leading drug treatment indicated for extreme fatigue and sleepiness.

Additionally, nighttime activity in NLS-4 treated rats was comparable to rats that did not undergo the fatigue procedure, the study's

"The fatigue procedure utilized in this

study induces a disruption in circadian activity, namely a decrease in motor activity during the dark period when rats are normally active,

and an increase in motor activity during the period of light when rats are largely inactive," said Dr. Jean-Charles Bizot, Ph.D.,

research manager of the study and Chief Executive Officer of Key-Obs in Orl ans, France. "In this preclinical model, we observed

NLS-4's clear motor-stimulating effect, which was superior to the widely prescribed fatigue treatment, modafinil. The motor-stimulating

effect of NLS-4 during the dark period suggests an improvement in recovery from the fatigue procedure and therefore is an indicator of

the drug candidate's potential to treat diseases in which chronic fatigue is a primary symptom."

Improvement in stimulation of laboratory animals

with NLS-4, with a beneficial effect on nictemeral rhythm, was reported in 2018 in a prior study conducted by the Department of Physiology,

Faculty of Biology and Medicine, Center for Integrative Genomics, University of Lausanne, Switzerland, which concluded that NLS-4 was

a highly potent wake-promoting drug that does not produce hypersomnia rebound. Additionally, the University of Lausanne study found that

sleep recovery after treatment with NLS-4 is characterized by less slow-wave sleep and delta activity compared to modafinil, suggesting

a lower need for recovery despite longer periods of drug-induced wakefulness. https://www.frontiersin.org/articles/10.3389/fnins.2018.00519/full

"These data provide additional evidence of

the potential beneficial effects of Lauflumide (NLS-4), which produces a lower need for sleep and better recovery from fatigue by properly

modulating wake-rest activity," said Eric Konofal, M.D., Ph.D., Chief Scientific Officer of NLS. "Excess fatigue, disturbed

sleep and concentration are the main symptoms found in patients who have contracted COVID-19, and today, there is no known treatment for

the improvement of Long-COVID symptoms. We are excited to bring this novel compound forward into clinical development, with the potential

ability to offer patients diagnosed with Long-COVID the chance for relief from their chronic fatigue symptoms."

About NLS-4 and Fatigue Symptoms Associated

with Viral Pandemics

NLS-4 is Lauflumide [2 - ((bis (4-fluorophenyl)

methyl) sulfinyl) acetamide], a next-generation selective dopamine reuptake inhibitor. NLS-4 is an enantiomeric form (R-isomer) that is

optically pure with an enantiomeric excess of more than 95% of bis (p-fluoro) phenyl ring-substituted derivative of modafinil (USPTO Patent

Application 20130295196, Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof: patent granted,

NLS-4 was found to weakly bind with neuropeptide

Y1 (NPY1), as a reverse agonist inhibitor modulating the development of depressive-like behavior and exerting histamine-2 receptor activity,

potentially alleviating neurocognitive disorders. A recent complementary assay profile has demonstrated that NLS-4 may exert inhibitory

activity on ACE2 and Cathepsin L, which offers potential promising treatment for COVID-19 patients.

It is important to recall that in the aftermath

of the pandemic of viral influenza with lethargic encephalitis, which had prevailed in Europe from 1915 to 1926, psychostimulants (amphetamine

salts) had been adopted as symptomatic treatment for neurological conditions caused by the virus. Amphetamines exhibited their beneficial

effects on the brain, attention, and fatigue in the patients who received them for treatment. Today, with the Covid-19 pandemic, we are

seeing the emergence of a new form of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) called Long-COVID.

to initiating clinical development of NLS-4 for the treatment of Long-COVID. The claim of this invention by patent application has been

registered under number EP21305944.

About NLS Pharmaceutics Ltd.

Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing

and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience

is a proprietary extended-release formulation of mazindol (mazindol ER) and is being developed for the treatment of narcolepsy. Mazindol

is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed

with narcolepsy in compassionate use programs. NLS has recently initiated a phase 2 study in the U.S. evaluating Quilience in adult

subjects suffering from Narcolepsy. Previously, NLS successfully completed a phase 2 study in the U.S. evaluating Nolazol

(mazindol controlled-release) in adult subjects suffering from ADHD. The study

met all primary and secondary endpoints and Nolazol was

well-tolerated. Quilience has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.

Up to 1/3rd of narcoleptic patients are also diagnosed with ADHD.

Safe Harbor Statement

This press release contains

express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements

when it discusses the potential benefits of NLS-4 (Lauflumide) for sufferers of Long-COVID

and its commitment to initiating clinical development of NLS-4 for the treatment of Long-COVID.

These forward-looking statements and their implications are based on the current expectations of the management of NLS only, and

are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the

forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described

in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or

successfully completing its clinical trials; NLS' products may not be approved by regulatory agencies, NLS' technology may not be validated

as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees

whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS' process; NLS'

products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in

real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS' patents may not

be sufficient; NLS' products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce

new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause

the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise

required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events

or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks

and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS' annual report on Form 20-F filed with

the SEC, which is available on the SEC's website, www.sec.gov.

Alex Zwyer, CEO: +41 41 618 80 00

Investor Relations Contact

Cindy Rizzo: +1 908-229-7050